Literature DB >> 7641200

Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.

T M Behr1, R M Sharkey, M E Juweid, R D Blumenthal, R M Dunn, G L Griffiths, H J Bair, F G Wolf, W S Becker, D M Goldenberg.   

Abstract

The renal uptake of radiolabeled antibody fragments and peptides is a problem in radioimmunodetection and radioimmunotherapy, especially with intracellular retained radiometals. The aim of this study was to develop suitable methods to reduce this kidney uptake. BALB/c mice or nude mice bearing the human GW-39 colon carcinoma xenograft were given i.p. injections of basic amino acids or a range of different basic amino acid derivatives, amino sugars, as well as cationic peptides. The effect of these agents on the biodistribution of Fab' and F(ab')2 fragments of different mAbs radiolabeled with 99mTc, 188Re, 111In, 88Y, or 125I was studied. Tumor and organ uptake was determined and compared to untreated mice. The kidney uptake of Fab' fragments was reduced 5-6-fold in a dose-dependent manner as compared to untreated controls. The uptake in all other organs, as well as the tumor, was unaffected. A similar reduction in renal retention was seen for all other intracellularly retained isotopes, as well as for F(ab')2 fragments. D- and L-isomers of lysine were equally effective whether given i.p. or p.o. D-glucosamine was effective, but its N-acetyl derivative was not. Basic polypeptides (e.g., poly-L-lysine) were also effective; their potency increased with increasing molecular weight. HPLC of the urine taken from treated animals showed the excretion of intact Fab', in contrast to mostly low-molecular-weight metabolites in the control group. These studies indicate that a variety of basic compounds is capable of inhibiting the tubular reabsorption of peptides and proteins, thus lowering the kidney uptake of antibody fragments significantly. On a molecular basis, the effect seems to essentially rely on the presence of a positively charged amino group. By reducing renal retention of antibody fragments, their role as imaging and therapeutic agents may be expanded.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641200

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Kidney failure after treatment with 90Y-DOTATOC.

Authors:  Tilmann Schumacher; Christian Waldherr; Jan Mueller-Brand; Helmut Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

2.  Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2011-05-05       Impact factor: 4.774

3.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

Review 4.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

Review 5.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

6.  Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.

Authors:  Benjamin J Hackel; Richard H Kimura; Sanjiv S Gambhir
Journal:  Radiology       Date:  2012-02-17       Impact factor: 11.105

7.  Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.

Authors:  Subhash C Chauhan; Maneesh Jain; Erik D Moore; Uwe A Wittel; Jing Li; Peter R Gwilt; David Colcher; Surinder K Batra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

8.  New nanosized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules.

Authors:  Mikako Ogawa; Celeste A S Regino; Bernardo Marcelino; Mark Williams; Nobuyuki Kosaka; L Henry Bryant; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

9.  Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.

Authors:  Karen Lam; Conrad Chan; Raymond M Reilly
Journal:  MAbs       Date:  2016-11-04       Impact factor: 5.857

Review 10.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.